secwatch.observer — SEC 8-K summary
======================================

Issuer:     RELMADA THERAPEUTICS, INC. (RLMD)
CIK:        0001553643
Form:       8-K
Filed at:   2026-03-09T23:59:59+00:00
Accession:  0001213900-26-024918
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 3.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Relmada raises $160M private placement; NDV-01 12-month Phase 2 CR rate 76%
---------------------------------------------------------------------------

- Oversubscribed PIPE financing of ~$160M gross from 29.47M shares at $4.75/share plus pre-funded warrants, expected to close March 11, 2026.
- Proceeds to be used for working capital and advancing R&D of product candidates, including NDV-01.
- NDV-01 Phase 2 in high-risk NMIBC: 12-month complete response rate 76% overall, 80% in BCG-unresponsive patients.
- No Grade 3+ treatment-related adverse events; no patient progressed to muscle-invasive disease or required cystectomy.
- Phase 3 RESCUE program planned for mid-2026 with two registrational pathways: 2L BCG-unresponsive and adjuvant intermediate-risk NMIBC.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1553643/000121390026024918/0001213900-26-024918-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1553643/000121390026024918/ea0280436-8k_relmada.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-024918

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer